Evidence map›Paper›PMID 27119828›Full record

ArticleGeorgian medical news2016

INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.

A Abutidze, N Bolokadze, N Chkhartishvili, L Sharvadze, T Tsertsvadze

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Georgian medical news, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Association of Treated and Untreated Chronic Hepatitis C With the Incidence of Active Tuberculosis Disease: A Population-Based Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  3. Type I interferons in tuberculosis: Foe and occasionally friend.The Journal of experimental medicine · 2018
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A AbutidzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi; I. Javakhishvili Tbilisi State University, Faculty of Medicine, Georgia.
N BolokadzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi; I. Javakhishvili Tbilisi State University, Faculty of Medicine, Georgia.
N ChkhartishviliInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi; I. Javakhishvili Tbilisi State University, Faculty of Medicine, Georgia.
L SharvadzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi; I. Javakhishvili Tbilisi State University, Faculty of Medicine, Georgia.
T TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi; I. Javakhishvili Tbilisi State University, Faculty of Medicine, Georgia.
Tbilisi State University · GE

Funding

Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
FIC NIH HHS D43 TW007124
6 · The paper itself

Abstract

Treatment of hepatitis C is necessary for ensuring higher life expectancy among HIV/HCV co-infected patients. However antiviral treatment for chronic HCV infection with Pegylated interferon (PEG-IFN) and Ribavirin (RBV) is associated with a variety of side effects. In Georgia up to 22% of HIV-infected patients were found to have active Tuberculosis (TB) and 22.4 to 32.6% had latent TB. The objective of this study was to describe the characteristics and clinical outcomes of tuberculosis in HIV/HCV co-infected patients receiving hepatitis C treatment with pegylated interferon and ribavirin and calculate incidence rate of TB. A retrospective study was conducted among HIV/HCV co-infected patients receiving antiviral treatment for chronic HCV infection at the Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia from December 2011 to May, 2015. A total of 420 HIV/HCV co-infected patients received HCV therapy with PEG-IFN and RBV during study period. Six of 420 patients developed TB while receiving PEG IFN + RBV therapy. These patients were on Antiretroviral treatment. Baseline HIV RNA load was <34 copies/ml and CD4+ cell counts >350 cells/mm3. No opportunistic infections were observed in all cases. Three of 6 patients had a previous positive tuberculin skin test (TST) result and had completed isoniazid chemoprophylaxis several years before TB diagnosis. In 2 patients TST was not performed. Only one patient had experienced a previous episode of TB and had completed the anti-TB therapy 1 year before hepatitis C treatment. In all patients TB was diagnosed during the PEG IFN + RBV therapy. Hepatitis C treatment was immediately stopped in all patients. The incidence rate of TB was 1.4 cases per 100 person-years (95% CI=0.58-2.97). Our study emphasizes the necessity of screening for latent TB prior to the initiation of chronic hepatitis C treatment with PEG IFN and RBV.

Indexed as

AdultAntiviral AgentsCoinfectionDrug Therapy, CombinationFemaleGeorgia (Republic)Hepatitis CHIV InfectionsHumansIncidenceInterferon-alphaMalePolyethylene GlycolsRetrospective StudiesRibavirinTuberculosis, PulmonaryAntiviral AgentsInterferon-alphaPolyethylene GlycolsRibavirin

Identifiers

PMID27119828
PMCPMC5113941
OpenAlexW2439693370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.